MindMed baut sein Arzneimittelspektrum und seine Führungsrolle in der Branche für Psychedelika-Medikamente weiter aus
MindMed Co-founders and Co-CEOs JR Rahn and Stephen Hurst to provide corporate update of activities and investor Q&A on July 2, 2020 at 1pm EST Basel, Switzerland — June 26, 2020-MindMed (DE:MMQ) , the leading neuro-pharmaceutical company for psychedelic inspired medicines is rapidly advancing its drug development pipeline and R&D activities since its listing on … Weiterlesen